Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
IPO Year:
Exchange: NYSE
Website: merck.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/25/2026 | $142.00 | Outperform | RBC Capital Mkts |
| 2/20/2026 | $140.00 | Overweight | Barclays |
| 2/13/2026 | $150.00 | Hold → Buy | Deutsche Bank |
| 1/8/2026 | $135.00 | Peer Perform → Outperform | Wolfe Research |
| 12/18/2025 | $130.00 | Market Perform → Outperform | BMO Capital Markets |
| 11/24/2025 | $125.00 | Equal Weight → Overweight | Wells Fargo |
| 11/13/2025 | $105.00 | Sector Outperform | Scotiabank |
| 10/13/2025 | $95.00 | Neutral | Citigroup |
| 9/17/2025 | $90.00 | Buy → Hold | Berenberg |
| 5/14/2025 | $84.00 | Buy → Neutral | Citigroup |
Fastest customizable press release news feed in the world
Expanded label for once-yearly parasiticide treatment for dogs now includes Haemaphysalis longicornis (Asian longhorned tick) and Amblyomma maculatum (Gulf Coast tick) for 12 months Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and Drug Administration (FDA) approved an expanded label for BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) in dogs. The updated indication adds treatment and control of Asian longhorned tick (H. longicornis) and Gulf Coast tick (A. maculatum) for 12 months, when administered as a single, veterinarian‑delive
Data show long-term effectiveness of GARDASIL®9 and GARDASIL® 14 years and 18 years, respectively, following vaccination with 3 doses Data on certain HPV-related oropharyngeal cancers reinforce the importance of vaccination for both females and males Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced it will present new clinical and real-world data reaffirming the long-term effectiveness of the company's 9-valent Human Papillomavirus (HPV) vaccine, GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) and its 4-valent HPV vaccine, GARDASIL® (Human Papillomavirus 4-valent Vaccine, Recombinant) against certain HPV-related cancers and diseases
Late-breaking presentation of results from the Phase 3 CORALreef AddOn trial evaluating enlicitide decanoate, Merck's investigational oral PCSK9 inhibitor, which may help address the cardiovascular (CV) epidemic Data from the Phase 2 CADENCE trial of WINREVAIRTM (sotatercept-csrk) in patients with the syndrome of combined post- and precapillary pulmonary hypertension and heart failure with preserved ejection fraction (CpcPH-HFpEF) to be featured as late-breaking presentation Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced new clinical data from the company's cardio-pulmonary pipeline will be presented at the American College of Cardiology's Annual
CALABASAS, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced data from the dose-escalation portion of its Phase 1/2 clinical trial for NEO212, the Company's novel oral bio-conjugated therapy and will host a conference call to discuss the data today at 9:00am ET. NeOnc has formally notified the FDA that the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial has reached Maximum Tolerated Dose (MTD) at Cohort 5 (810 mg, Days 1–5, 28-day cycle) following a second
LAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/OHARA Pharmaceutical), Tovecimig (CTX-009) (Compass Therapeutics), Lenvatinib mesylate (LENVIMA) (Merck/Eisai), and others will further boost the market growth. Recently published Biliary Tract Cancer Market Insights report includes a comprehensive understanding of current
KEYTRUDA plus paclitaxel with or without bevacizumab is the first PD-1 inhibitor-based regimen to show a statistically significant improvement in OS regardless of PD-L1 status Results from the final analysis of the Phase 3 KEYNOTE-B96 trial to be presented during a Best Oral Session at the European Society of Gynaecological Oncology 2026 Congress Positive EU CHMP opinion granted for KEYTRUDA plus paclitaxel with or without bevacizumab in certain adults with PD-L1 (CPS ≥1) platinum-resistant ovarian carcinoma who have received one or two prior systemic treatment regimens Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced results from the final analy
The only JAK inhibitor approved in the U.S. for the control of pruritus associated with allergic dermatitis in dogs six months of age and older Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today the U.S. Food and Drug Administration (FDA) approval of NUMELVI™ (atinvicitinib tablets) – the first and only second-generation Janus kinase (JAK) inhibitor indicated for the control of pruritus associated with allergic dermatitis in dogs six months of age and older. The product is expected to be available at veterinary clinics and hospitals nationwide in spring 2026. "Merck Anima
DOR/ISL is the first non-INSTI, two-drug regimen to demonstrate non-inferiority and a similar safety profile at Week 48 to BIC/FTC/TAF in adults living with HIV-1 who had not previously received antiretroviral treatment DOR/ISL maintained virologic suppression at Week 96 in adults with virologically suppressed HIV-1 who switched from other oral antiretroviral therapies, including BIC/FTC/TAF Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from three pivotal Phase 3 trials evaluating the investigational, once-daily, oral, two-drug regimen of doravirine/islatravir [DOR/ISL (100 mg/0.25 mg), (MK-8591A)] in adults with HIV-
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that Caroline Litchfield, executive vice president and chief financial officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, Mar. 3, 2026, at 1:50 p.m. EST. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this weblink. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge sci
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today highlighted steps to evolve the structure of its Human Health organization to ensure strong commercial execution of launches across diverse therapeutic areas, positioning the company for continued commercial success. As part of this evolution, Merck is organizing its Human Health business into an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. This structure will enable Merck to sustain long-term leadership in oncology, while maintaining a sharp focus in support of a growing number of launches across an increasingly broad and diverse portfolio. In support of the new Human He
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
RBC Capital Mkts initiated coverage of Merck with a rating of Outperform and set a new price target of $142.00
Barclays initiated coverage of Merck with a rating of Overweight and set a new price target of $140.00
Deutsche Bank upgraded Merck from Hold to Buy and set a new price target of $150.00
Wolfe Research upgraded Merck from Peer Perform to Outperform and set a new price target of $135.00
BMO Capital Markets upgraded Merck from Market Perform to Outperform and set a new price target of $130.00
Wells Fargo upgraded Merck from Equal Weight to Overweight and set a new price target of $125.00
Scotiabank initiated coverage of Merck with a rating of Sector Outperform and set a new price target of $105.00
Citigroup resumed coverage of Merck with a rating of Neutral and set a new price target of $95.00
Berenberg downgraded Merck from Buy to Hold and set a new price target of $90.00
Citigroup downgraded Merck from Buy to Neutral and set a new price target of $84.00
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
3 - Merck & Co., Inc. (0000310158) (Issuer)
4 - Merck & Co., Inc. (0000310158) (Issuer)
4 - Merck & Co., Inc. (0000310158) (Issuer)
4 - Merck & Co., Inc. (0000310158) (Issuer)
4 - Merck & Co., Inc. (0000310158) (Issuer)
4 - Merck & Co., Inc. (0000310158) (Issuer)
4 - Merck & Co., Inc. (0000310158) (Issuer)
4 - Merck & Co., Inc. (0000310158) (Issuer)
4 - Merck & Co., Inc. (0000310158) (Issuer)
4 - Merck & Co., Inc. (0000310158) (Issuer)
10-K - Merck & Co., Inc. (0000310158) (Filer)
13F-HR - Merck & Co., Inc. (0000310158) (Filer)
144 - Merck & Co., Inc. (0000310158) (Subject)
8-K - Merck & Co., Inc. (0000310158) (Filer)
8-K - Merck & Co., Inc. (0000310158) (Filer)
424B5 - Merck & Co., Inc. (0000310158) (Filer)
FWP - Merck & Co., Inc. (0000310158) (Subject)
424B5 - Merck & Co., Inc. (0000310158) (Filer)
13F-HR - Merck & Co., Inc. (0000310158) (Filer)
10-Q - Merck & Co., Inc. (0000310158) (Filer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Merck & Co., Inc. (0000310158) (Issuer)
4 - Merck & Co., Inc. (0000310158) (Issuer)
Live finance-specific insights
CALABASAS, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced data from the dose-escalation portion of its Phase 1/2 clinical trial for NEO212, the Company's novel oral bio-conjugated therapy and will host a conference call to discuss the data today at 9:00am ET. NeOnc has formally notified the FDA that the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial has reached Maximum Tolerated Dose (MTD) at Cohort 5 (810 mg, Days 1–5, 28-day cycle) following a second
Reports Strength in Oncology and Animal Health, Plus Increasing Contributions From WINREVAIR and CAPVAXIVE Fourth-Quarter Worldwide Sales Were $16.4 Billion (5% Growth; 4% Growth ex-FX) Fourth-Quarter GAAP EPS Was $1.19; Non-GAAP EPS Was $2.04; GAAP and Non-GAAP EPS Include a Charge of $0.05 per Share for the Acquisition of MK-8690 Sole Global Rights Full-Year Worldwide Sales Were $65.0 Billion (1% Growth; 2% Growth ex-FX) KEYTRUDA/KEYTRUDA QLEX Sales Were $31.7 Billion (7% Growth Both Nominally and ex-FX); Includes KEYTRUDA QLEX Sales of $40 Million WINREVAIR Sales Were $1.4 Billion CAPVAXIVE Sales Were $759 Million GARDASIL/GARDASIL 9 Sales Were $5.2 Billion (39% Decli
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company's common stock for the second quarter of 2026. Payment will be made on April 7, 2026, to shareholders of record at the close of business on March 16, 2026. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-inten
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, will hold its fourth-quarter and full-year 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Tuesday, Feb. 3. During the call, company executives will provide an overview of Merck's performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com. All participants may join the call by dialing (800) 369-3351 (U.S. and C
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company's common stock for the first quarter of 2026. Payment will be made on Jan. 8, 2026, to shareholders of record at the close of business on Dec. 15, 2025. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intens
Total Worldwide Sales Were $17.3 Billion, an Increase of 4% From Third Quarter 2024; Excluding the Impact of Foreign Exchange, Sales Grew 3% KEYTRUDA Sales Grew 10% to $8.1 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 8% WINREVAIR Sales Were $360 Million; Growth of 141% Both Nominally and Excluding the Impact of Foreign Exchange CAPVAXIVE Sales Were $244 Million GARDASIL/GARDASIL 9 Sales Declined 24% to $1.7 Billion; Excluding the Impact of Foreign Exchange, Sales Declined 25% Animal Health Sales Grew 9% to $1.6 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 7% GAAP EPS Was $2.32; Non-GAAP EPS Was $2.58; GAAP and Non-GAAP EPS Include a Ch
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, Oct. 30. During the call, company executives will provide an overview of Merck's performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com. All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Fr
Total Worldwide Sales Were $15.8 Billion, a Decrease of 2% From Second Quarter 2024 Both Nominally and Excluding the Impact of Foreign Exchange KEYTRUDA Sales Were $8.0 Billion, Growth of 9% Both Nominally and Excluding the Impact of Foreign Exchange WINREVAIR Sales Were $336 Million Animal Health Sales Were $1.6 Billion, Growth of 11% Both Nominally and Excluding the Impact of Foreign Exchange GARDASIL/GARDASIL 9 Sales Were $1.1 Billion, a Decline of 55% Both Nominally and Excluding the Impact of Foreign Exchange GAAP EPS Was $1.76; Non-GAAP EPS Was $2.13; GAAP and Non-GAAP EPS Include a Charge of $0.07 per Share for Closing of Hengrui Pharma License Agreement Announce
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.81 per share of the company's common stock for the fourth quarter of 2025. Payment will be made on Oct. 7, 2025 to shareholders of record at the close of business on Sept. 15, 2025. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-inten
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, will hold its second-quarter 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Tuesday, July 29. During the call, company executives will provide an overview of Merck's performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com. All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Fr
This live feed shows all institutional transactions in real time.
SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)
SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)
SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)
SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)
Live Leadership Updates
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today highlighted steps to evolve the structure of its Human Health organization to ensure strong commercial execution of launches across diverse therapeutic areas, positioning the company for continued commercial success. As part of this evolution, Merck is organizing its Human Health business into an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. This structure will enable Merck to sustain long-term leadership in oncology, while maintaining a sharp focus in support of a growing number of launches across an increasingly broad and diverse portfolio. In support of the new Human He
CD388 is an investigational long-acting, strain-agnostic antiviral agent currently in Phase 3, designed to prevent influenza infection in individuals at higher risk of influenza complications Acquisition aligns with Merck's science-led business development strategy, diversifying and expanding the company's pipeline Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc. (NASDAQ:CDTX) ("Cidara"), a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for $221.50 per share in cash, for a tot
Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of integrated payment processing solutions, today announced the appointment of Robert Houser as Chief Financial Officer of the Company, effective September 8, 2025. "We are extremely excited to welcome Rob to REPAY. Rob brings over a decade of divisional CFO and operational experience within the payment industry to help him contribute immediately. Rob has held key strategic roles across his career and will be a great partner in running our company," said John Morris, Co-Founder and CEO. Most recently, Rob served as the Group CFO of the Public Sector and Advisor at Conduent Incorporated (NASDAQ:CNDT)
Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov
WILMINGTON, Del., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) has announced the appointment of Sanat Chattopadhyay, executive vice president of Merck & Company (NYSE:MRK) to its Board of Directors. Chattopadhyay will serve on the Board's Environmental, Health, Safety, and Quality and Governance and Nominating Committees, effective November 13, 2023. Prior to Merck, Chattopadhyay held leadership positions at Wyeth Pharmaceuticals, Aventis, Hoechst Marion Roussel and Hoechst India. As previously announced, Jay V. Ihlenfeld who has served as a director since 2017, and Brendan M. Cummins, who joined the board in 2012 have decided not to stand for re-election at Ashland's Annua
Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer Arun Balakumaran M.D., Ph.D, appointed Chief Medical Officer of Replay to support the Company's genomic medicine and engineered NK cell therapy pipelineFormer Chief Medical Officer of allogeneic CAR-T cell company Allogene Therapeutics and seasoned industry immuno-oncology, and cell and gene therapy expert Dr. Balakumaran also appointed CMO of Syena, Replay's engineered NK cell therapy product company pioneering first-in-class engineered T-cell Receptor Natural Killer cell (TCR-NK) therapy San Diego, California and London, UK, May 18, 2023 – Replay, a genome writing company reprogramming biology by writing and deliver
Eikon Therapeutics Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Kenneth C. Frazier as an independent director effective April 1, 2022. Among the world's most admired global business leaders, Mr. Frazier is the executive chairman and former CEO of Merck (NYSE:MRK), chairman of health assurance initiatives at the venture capital firm General Catalyst, and a director of Exxon Mobil Corporation (NYSE:XOM). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220331005316/en/Kenneth C. Frazi
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Dr. Roy D. Baynes, head of Global Clinical Development (GCD) and Chief Medical Officer, Merck Research Laboratories (MRL), will be retiring from Merck in July. Dr. Baynes will be succeeded by Dr. Eliav Barr, effective April 1, 2022. Dr. Baynes will continue to report to Dr. Dean Y. Li, president, Merck Research Laboratories, until his retirement. "Roy is one of the world's pre-eminent oncologists and clinical development experts, and his masterful spearheading of the development of KEYTRUDA leaves an indelible mark on Merck, on oncology and on the lives of patients and their families. As textbooks are
Organon (NYSE:OGN), a global women's health company, today announced the appointment of Meghan Rivera as US Managing Director. With over 20 years of commercial experience in bio-pharmaceutical organizations and digital therapeutics, Ms. Rivera will be responsible for leading Organon's 400-strong US Commercial Operations team, maximizing growth potential across the company's portfolio of women's health, biosimilars, and established brands treatment areas. Ms. Rivera has significant commercial experience including roles in bio-pharmaceutical and digital therapeutic organizations and agency partners. She has extensive women's health expertise, having held leadership roles in commercial and ge
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the independent members of the Merck Board of Directors have appointed Thomas H. Glocer as independent lead director effective immediately. Mr. Glocer has served on the Merck Board of Directors since 2007. He has extensive management, operational, technology and international business expertise, including his history of accomplishment and executive leadership while chief executive officer and a director of Thomson Reuters Corporation. Mr. Glocer also serves as independent lead director at Morgan Stanley. "Since Tom joined our board in 2007, his expertise, counsel and guidance have been invaluable to